FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Inclusion Criteria

• •Histologically confirmed cancer of the colon or rectum with documented metastasis
• •Measurable disease per RECIST v. 1.1
• •Not candidates for curative surgery or curative radiation
• •Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
• •Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
• •Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
• •Tumor confirmed to harbor a known RAS mutation per a standard local testing method
• •ECOG performance status of 0 or 1
• •Patients must have adequate hematological, renal, and hepatic function
• •Female patients of childbearing potential must have a negative pregnancy test
• •Life expectancy of at least 6 months